EFM
E Fund Management Portfolio holdings
AUM
$3.37B
This Fund
S&P 500
1 Year Est. Return
–
AUM
$3.37B
AUM Growth
–
Holding
489
Top Buys
| 1 | +$483M | |
| 2 | +$247M | |
| 3 | +$186M | |
| 4 |
TSMC
TSM
|
+$179M |
| 5 |
Microsoft
MSFT
|
+$143M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 52.03% |
| 2 | Consumer Discretionary | 19.21% |
| 3 | Communication Services | 9.64% |
| 4 | Healthcare | 4.63% |
| 5 | Consumer Staples | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Allogene Therapeutics
ALLO
$792M
| $86.6K | ﹤0.01% |
+35,492
|
|
||
|
PURR
477
Hyperliquid Strategies Inc
PURR
$795M
| $85K | ﹤0.01% |
+16,691
|
|
||
478
Vanda Pharmaceuticals
VNDA
$430M
| $80.2K | ﹤0.01% |
+11,603
|
|
||
479
Lexeo Therapeutics
LXEO
$512M
| $72.8K | ﹤0.01% |
+12,683
|
|
||
480
Verastem
VSTM
$578M
| $72.7K | ﹤0.01% |
+13,717
|
|
||
481
Arbutus Biopharma
ABUS
$930M
| $69.5K | ﹤0.01% |
+15,443
|
|
||
482
Myriad Genetics
MYGN
$480M
| $66.2K | ﹤0.01% |
+14,709
|
|
||
483
Ocugen
OCGN
$653M
| $64.4K | ﹤0.01% |
+35,562
|
|
||
484
Rocket Pharmaceuticals
RCKT
$427M
| $63.5K | ﹤0.01% |
+17,751
|
|
||
485
MiMedx Group
MDXG
$508M
| $61.4K | ﹤0.01% |
+15,543
|
|
||
486
Akebia Therapeutics
AKBA
$378M
| $57.2K | ﹤0.01% |
+41,119
|
|
||
487
Anavex Life Sciences
AVXL
$337M
| $55.5K | ﹤0.01% |
+18,070
|
|
||
488
Invivyd
IVVD
$492M
| $50.1K | ﹤0.01% |
+38,502
|
|
||
489
Perspective Therapeutics
CATX
$479M
| $48.7K | ﹤0.01% |
+11,667
|
|